| Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over | HST33 | | |
| Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) | TA1058 | | |
| Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour | IPG800 | | |
| Robot-assisted surgery for soft tissue procedures: early value assessment | HTE21 | | |
| Robot-assisted surgery for orthopaedic procedures: early value assessment | HTE22 | | |
| Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA1055 | | |
| Molnupiravir for treating COVID-19 | TA1056 | | |
| Relugolix–estradiol–norethisterone for treating symptoms of endometriosis | TA1057 | | |
| Cladribine for treating active relapsing forms of multiple sclerosis | TA1053 | | |
| Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over | TA1054 | | |
| Early and locally advanced breast cancer: diagnosis and management | NG101 | | |
| Burosumab for treating X-linked hypophosphataemia in children and young people | HST8 | | |
| Suspected cancer: recognition and referral | NG12 | | |
| Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B | HST32 | | |
| Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over | TA1051 | | |
| Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal) | TA1052 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable | TA1048 | | |
| Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia | TA1049 | | |
| Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over | TA1050 | | |
| Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma | TA1046 | | |
| Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal) | TA1047 | | |
| Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension | IPG801 | | |
| 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites | TA1045 | | |
| Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection | TA1043 | | |
| Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over | TA1044 | | |
| Advanced breast cancer: diagnosis and treatment | CG81 | | |
| Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer | TA1041 | | |
| Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer | TA1042 | | |
| Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over | TA1038 | | |
| Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over | TA1039 | | |
| Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy | TA1040 | | |
| Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over | TA1033 | | |
| Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment | HTE12 | | |
| Intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary intervention | IPG802 | | |
| Ovarian cancer | QS18 | | |
| Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment | TA1036 | | |
| Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA1037 | | |
| Digital technologies to support self-management of COPD: early value assessment | HTE19 | | |
| Tobacco: preventing uptake, promoting quitting and treating dependence | NG209 | | |
| Epilepsies in children, young people and adults | NG217 | | |
| Gambling-related harms: identification, assessment and management | NG248 | | |
| Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease | TA1035 | | |
| Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours | TA1034 | | |
| Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) | TA1032 | | |
| Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over | TA1031 | | |
| Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 years | NG247 | | |
| Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) | TA1028 | | |
| Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) | TA1029 | | |
| Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer | TA1030 | | |
| Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban | TA697 | | |